Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by AstraZeneca
< Previous
1
2
3
4
5
6
Next >
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
February 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
February 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
February 16, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Full year and Q4 2023 Financial Results
February 08, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
February 06, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors
January 29, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
January 22, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
January 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
December 26, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
GRCL
WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
December 21, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
December 12, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca advances scientific leadership in hematology at ASH 2023
November 29, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
November 20, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
November 17, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
November 09, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity
November 08, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
November 03, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)
October 24, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
October 23, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
October 23, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
October 23, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
October 22, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
October 21, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
October 21, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
October 20, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
October 16, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge
October 12, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
October 11, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
September 22, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment
September 14, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.